Anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002

Pharmacoepidemiology and Drug Safety

Volumn 15, Issue 7, 2006, Pages 494-503

  Mancini, Julien ^a   Thirion, Xavier ^a,b   Masut, Alain ^c   Saillard, Carine ^a   Pradel, Vincent ^a,d   Romain, Fanny ^a   Pastor, Marie Jospeh Jean ^e   Coudert, Christine ^c   Micallef, Joëlle ^a,d  

^a School of Medicine   (France)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c Social Security System   (France)

^d TIMONE HOSPITAL   (France)

^e Regional Pharmacovigilance Centre   (France)

Author keywords

Adolescents; Antidepressants; Anxiolytics; Hypnotics; Pharmacoepidemiology; Prescriptios databases; Psychotropic drugs

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BROMAZEPAM; BUSPIRONE; CLOBAZAM; CLORAZEPATE POTASSIUM; CLOTIAZEPAM; DIAZEPAM; ESTAZOLAM; FLUNITRAZEPAM; FLUOXETINE; HYDROXYZINE; HYPNOTIC AGENT; LOPRAZOLAM; LORAZEPAM; LORMETAZEPAM; MEPROBAMATE; NIAPRAZINE; NITRAZEPAM; NORDAZEPAM; PAROXETINE; PRAZEPAM; PSYCHOTROPIC AGENT; SERTRALINE; TEMAZEPAM; TRIAZOLAM; UNINDEXED DRUG; ZOLPIDEM; ZOPICLONE;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG SURVEILLANCE PROGRAM; FEMALE; FRANCE; HEALTH INSURANCE; HUMAN; MALE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; REIMBURSEMENT; SEX RATIO;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; CROSS-SECTIONAL STUDIES; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; FRANCE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; PRESCRIPTIONS, DRUG; SEASONS; TIME FACTORS;

EID: 33746647754     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1258     Document Type: Article

References (36)

1. Beck F, Legleye S. Usages de drogues et contextes d'usage entre 17 et 19 ans, évolutions récentes - ESCAPAD 2002. OFDT: Paris, 2003; 164.
2. Arwidson P, Gautier A, Guilbert P. Douleurs, consommation de soins et médicaments. In Baromètre santé jeunes 97/98, CFES (ed). CFES: Vanves, 1998; 267-281.
3. Choquet M, Ledoux S. Adolescents. Enquête nationale. INSERM: Paris, 1994; 346.
4. Chambaretaud S. La consommation de médicaments dans les principaux pays industrialisés. Drees Etudes et résultats 2000; 47: 1-8.
5. Pigeon M, Criquilion B, Lancry PJ. MEDIC' Assurance Maladie - Les médicaments remboursés par le Régime Général d'Assurance Maladie au cours des années 2001 et 2002. CNAMTS: Paris, 2003; 114.
6. Zarifian E. Le prix du bien-être. Psychotropes et société. Odile Jacob: Paris, 1996; 285.
7. Costes JM, Bello PY, Palle C. Les addictions en France: Etat des lieux. Rev Prat 2003; 53: 1299-1303.
8. Observatoire Français des Drogues et des Toxicomanies. Drogues et Dépendances, indicateurs et tendances. OFDT: Paris, 2002; 368.
9. Pommereau X. Santé des jeunes. Orientations et actions à promouvoir en 2002. Ministère de l'emploi et de la solidarité: Paris, 2002; 33.
10. Weill A, Ricordeau P, Vallier N, Bourrel R, Fender P, Allemand H. L'analyse des prestations remboursées par l'assurance maladie: matériel et méthodes. Diabetes Metab 2000; 26(Suppl 6): 49-54.
11. Thirion X, Lapierre V, Micallef J, et al. Buprenorphine prescription by general practitioners in a French region. Drug Alcohol Depend 2002; 65: 197-204.
12. Lapeyre-Mestre M, Llau ME, Gony M, et al. Opiate maintenance with buprenorphine in ambulatory care: a 24-week follow-up study of new users. Drug Alcohol Depend 2003; 72: 297-303.
13. Madsen H, Andersen M, Hallas J. Drug prescribing among Danish children: a population-based study. Eur J Clin Pharmacol 2001; 57: 159-165.
14. Strom BL. Pharmacoepidemiology (3rd edn). Wiley: Chichester, 2000; 800.
15. Lecadet J, Vidal P, Baris B, et al. Médicaments psychotropes: consommation et pratiques de prescription en France métropolitaine. II. Données et comparaisons régionales, 2000. Revue Médicale de l'Assurance Maladie 2003; 34: 233-248.
16. The European Agency for the Evaluation of Medicinal Products. Note for Guidance on Clinical Investigation of Medicinal Products in the Paediatric Population. EMEA: London, 2000; 12.
17. World Health Organisation Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical classification System (ATC). World Health Organisation: Oslo, 2002.
18. Lecadet J, Vidal P, Baris B, et al. Médicaments psychotropes: consommation et pratiques de prescription en France métropolitaine. I. Données nationales, 2000. Revue Médicale de l'Assurance Maladie 2003; 34: 75-84.
19. Pommier J, Billot L, Mouchtouris A, Deschamps JP, Romero MI, Zubarew T. French adolescent attitudes towards informal care for physical and emotional or relational problems. Acta Paediatr 2002; 91: 466-474.
20. De Peretti C, Leselbaum N. Les lycéens parisiens et les substances psychoactives: évolutions. OFDT, INRP, Paris X: Paris, 1999; 163.
21. Choquet M, Ledoux S, Hassler C. Alcool, cannabis et autres drogues illicites parmi les élèves de collège et de lycée: ESPAD 99 france, Tome I. OFDT: Paris, 2002; 148.
22. Ledoux S, Choquet M. Usage de médicaments à but psychotrope à l'adolescence: pourquoi plus les filles? Etude sur un échantillon des 12-20 ans scolarisés en Haute-Marne (France). Rev Epidemiol Sante Publique 1994; 42: 216-223.
23. Skurtveit S, Rosvold EO, Furu K. Use of psychotropic drugs in an urban adolescent population: the impact of health-related variables, lifestyle and sociodemographic factors - The Oslo Health Study 2000-2001. Pharmacoepidemiol Drug Safe 2005; 14: 277-283.
24. Hansen EH, Holstein BE, Due P, Currie CE. International survey of self-reported medicine use among adolescents. Ann Pharmacother 2003; 37: 361-366.
25. Deleau N. EFFEXOR® et EFFEXOR® LP (venlafaxine): confirmation de la contre-indication chez les patients de moins de 18 ans. Vigilances 2003; 17: 2.
26. Waechter F. Paroxetine must not be given to patients under 18. Br Med J. 2003; 326: 1282.
27. Ryan ND. Treatment of depression in children and adolescents. Lancet 2005; 366: 933-940.
28. European Medicines Agency Press office. CHMP Meeting on Paroxetine and Other SSRIs. EMEA: London, 2004; 4.
29. European Medicines Agency Press office. European Medicines Agency Finalises Review of Antidepressants in Children and Adolescents. EMEA: London, 2005; 4.
30. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. Br Med J 2000; 320: 79-82.
31. Turner S, Longworth A, Nunn AJ, Choonara I. Unlicensed and off label drug use in paediatric wards: prospective study. Br Med J 1998; 316: 343-345.
32. Martin RM, Wilton LV, Mann RD, Steventon P, Hilton SR. Unlicensed and off label drug use for paediatric patients. General practitioners prescribe SSRIs to children off label. Br Med J 1998; 317: 204.
33. Horen B, Montastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 2002; 54: 665-670.
34. Chalumeau M, Treluyer JM, Salanave B, et al. Off label and unlicensed drug use among French office based paediatricians. Arch Dis Child 2000; 83: 502-505.
35. Ambrosini PJ, Wagner KD, Biederman J, et al. Multicenter open-label sertraline study in adolescent outpatients with major depression. J Am Acad Child Adolesc Psychiatry 1999; 38: 566-572.
36. Garcia Rodriguez LA, Perez GS. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998; 45: 419-425.